RVMD - Revolution Medicines, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.05
+0.74 (+2.61%)
At close: 4:00PM EST

29.75 +0.70 (2.41%)
Pre-Market: 8:08AM EST

Stock chart is not supported by your current browser
Previous Close28.31
Open28.01
Bid27.00 x 800
Ask33.00 x 1400
Day's Range27.15 - 29.69
52 Week Range27.15 - 32.49
Volume764,900
Avg. Volume3,104,900
Market Cap1.696B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-21.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    REDWOOD CITY, Calif., Feb. 18, 2020 -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive.

  • The Funded: 7 Bay Area startups raise over $135M at week's end
    American City Business Journals

    The Funded: 7 Bay Area startups raise over $135M at week's end

    Seven Bay Area companies raised over $135 million in funding at the end of the week. Here's more on that and other venture news.

  • MarketWatch

    Revolution Medicines shares soar 85% in trading debut after IPO priced at top end of range

    Shares of Revolution Medicines Inc. , a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a revised range. The Redwood City, California-based company sold 14 million shares priced at $17 each to raise $238 million. The deal was upsized from an earlier plan to offer 10 million shares priced at $14 to $16 each. JPMorgan, Cowen, SVB Leerink and Guggenheim were underwriters on the deal. Proceeds will be used to fund R&D, to move toward clinical trials for some candidates and for general corporate purposes. "We are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways," says the prospectus.

  • MarketWatch

    Revolution Medicines prices IPO at $17 a share

    Revolution Medicines Inc. priced its initial public offering at $17 a share Wednesday evening, and will collect about $238 million. The clinical-stage oncology company said it would sell 14 million shares at that price, after increasing the size and target price of its offering Tuesday. Underwriters -- led by JPMorgan, Cowen, SVB Leerink and Guggenheim -- have access to an additional 2.1 million shares that could push the total higher. Revolution shares are expected to begin trading Thursday morning on the Nasdaq exchange under the ticker symbol RVMD.

  • GlobeNewswire

    Revolution Medicines Announces Pricing of Initial Public Offering

    REDWOOD CITY, Calif., Feb. 12, 2020 -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its initial public offering of 14,000,000 shares of common stock.

  • MarketWatch

    Revolution Medicines increases size of planned IPO and raises price range

    Revolution Medicines, a clinical-stage oncology company, on Tuesday increased the size of its planned initial public offering and raised the price range. In a filing with the Securities and Exchange Commission, the Redwood City, California-based company said it is now planning to offer 14 million shares priced at $16 to $17 each. An earlier filing said it would offer just 10 million shares priced at $14 to $16 each. JPMorgan, Cowen, SVB Leerink and Guggenheim are underwriters on the deal. Proceeds will be used to fund R&D, to move toward clinical trials for some candidates and for general corporate purposes. "We are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways," says the prospectus.